Search

Search Constraints

You searched for: Author/Creator Ponziani, F.R.

Search Results

2. Clinical impact of comorbidities in an Italian NAFLD cohort. (February 2019)

3. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Issue 1 (16th February 2017)

4. Effectiveness of HCV antiviral treatment in patients with cirrhosis or advanced fibrosis and end-stage kidney disease on dialysis. Issue 1 (16th February 2017)

5. First steps towards understanding the dynamic evolution of gut microbiota in different stages of liver disease. (15th February 2015)

9. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis. Issue 1 (February 2018)

10. Long-term results from the Italian real-world experience on obeticholic acid treatment in primary biliary cholangitis: The RECAPITULATE study. (March 2023)